Shots:

• The P-II/III ARTISTS 1 & P-III ARTISTS 2 studies involve assessing of Austedo vs PBO in 119 & 158 pediatric patients (6-16 yrs.) in a ratio (1:1) & (1:1:1) over 12 & 8wks. dosing for the treatment of tics in patients with mod. to severe TS
• The P-II/III ARTISTS 1 & P-III ARTISTS 2 studies resulted in not meeting its 1EPs i.e. reduction in motor and phonic tics as assessed by YGTSS-TTS. The studies were conducted in collaboration with Teva and Nuvelution Pharma
• Austedo is a VMAT2 inhibitor and has received the US FDA’s approval for the treatment of chorea associated with Huntington’s disease in Apr’2017 and for tardive dyskinesia in Aug’2017

Click here to­ read full press release/ article | Ref: Businesswire | Image: Teva